The Jonathan Cohen-Gold Interview - CEO of Houdini Bio🧬

Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's innate immune system recognizes it as a threat and shuts it down. Houdini Bio's platform uses AI and proprietary Houdini elements, short 100 base pair sequences, to give the therapeutic DNA a self-hallmark, essentially camouflaging it against the cell's defense machinery without touching the pathway globally. The result is better transgene expression, safer delivery, and a plug-and-play approach that works across AAV, lentiviral, and other delivery formats. 0:00 Introduction 0:10 Welcome Jonathan Cohen-Gold, Houdini Bio 0:49 The problem: cells reject foreign DNA 1:39 Why this kills gene therapies 3:19 The market adoption crisis 4:42 Why previous approaches failed 5:11 The HUSH complex explained 6:15 Jonathan's PhD and unfair advantage 9:52 Building Houdini Bio from scratch 11:45 The Venture Science Doctorate 12:25 Academic system vs entrepreneurship 13:28 Houdini's platform and approach 14:00 Houdini elements explained 16:23 AI and the closed loop wet lab system 17:55 Current data and proof points 20:43 Rescuing failed gene therapies 22:18 What's next for Houdini Bio 25:22 The big opportunity 26:17 Investors and funding 29:19 Closing and what to watch for